Bausch + Lomb Corporation
BLCOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeBausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and. The company carries a $6.33B market cap, placing it firmly in the mid-cap category. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical.
Market Cap
$6.33B
Beta
0.56
P/E (TTM)
—
P/E (Fwd)
16.22
EPS (TTM)
$-0.48
EPS (Fwd)
$1.09
ROE
-2.5%
ROA
1.8%
Cash
$367.0M
Total Debt
$5.11B
Free CF
$323.0M
52W Change
20.3%
Annual Financials
Cash vs Debt
Where BLCO stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, BLCO finished 9.29% above its 150-day moving average ($16.47) and 8.96% above its 200-day moving average ($16.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is BLCO overbought or oversold?
At the September 3, 2026 close, BLCO's RSI(14) was 75.5, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, BLCO has $367.0M in cash with $5.11B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $323.0M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -2.5% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 1.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.77B (2022) to $5.10B (2025), reflecting a 35% increase over the period.
With a beta below 0.7, Bausch + Lomb Corporation typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Bausch + Lomb Corporation and its sector.